 DURHAM, N.C.--BUSINESS WIRE--Aerie Pharmaceuticals, Inc. NASDAQ: AERI, an ophthalmic pharmaceutical company, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer presented an overview on Aeries retina product candidates, at the Ophthalmology Innovation Summit Retina Innovation Showcase. The slide presentation addresses Aeries proprietary PRINT drug delivery platform and retina product candidates AR-1105 dexamethasone implant, Phase 3 ready, AR-13503 Rho kinaseProtei 